Amadeus invests in Inotec’s wound care technology

Amadeus a global technology investor, has announced an investment in Inotec Natrox, a maker of mobile medical devices designed to heal chronic, hypoxic wounds.

Natrox has been designed to ensure that wounds do not suffer from a loss of oxygen with a simple, cost-effective application which treats a broad spectrum of chronic health problems.

Amadeus will bring investment and expertise to Inotec, based in Cambridge, UK, to enable the company to carry out large scale clinical trials and to broaden the scope of application of its innovative Natrox products.

The global investor in dynamic start-ups says it will also draw on its worldwide network to help Inotec establish commercial agreements and grow its presence internationally.

Pierre Socha, Investment Manager, Amadeus Capital Partners, said: “Inotec’s proprietary technology has the potential to profoundly improve standards of care for hard-to-heal and chronic wounds, a large and growing market. Natrox can be used at home as well as in hospital, alleviating pressure on stretched healthcare systems and materially improving quality of life for patients,”

Trevor Stanley, Inotec CEO, commented: “The global wound-care market is projected to grow to $18.3 billion globally in 2019. Amadeus’ investment will enable us to deliver advanced and highly effective oxygen-based wound-care technology across the world.”